Citations

Clear

395 citation(s) found for "Seidman, J G".

A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01
Borad, Mitesh J. , Busset, Michele Droz Dit , Javle, Milind , Shaib, Walid L. , Personeni, Nicola , Mody, Kabir , Bergamo, Francesca, Harris, William P., Damjanov, Nevena , Macarulla, Teresa , Brandi, Giovanni , Masi, Gianluca , Abou‐Alfa, Ghassan K. , Hálfdánarson, Þorvarður R. , Knox, Jennifer, Tam, Vincent C. , Bernat, Mathieu, Engelhardt, Marc , Friedmann, Silke, Häckl, Manuel, McKernan, Phil, Saulay, Mikael, Goff, Laura W. , Hollebecque, Antoine , Adeva, Jorge , Jeffry Evans, Thomas R. , Bridgewater, John , Foerster, Friedrich , Kendall, Stephan DiSean, Roth, Gaël , Cunningham, David, Vogel, Arndt , Niger, Monica , Mahipal, Amit , Mazzaferro, Vincenzo

Mayo Clinic

Hepatology | October 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/hep.0000000000001902 | PMID 42937546 Get It

Background & Aims: To evaluate safety and efficacy of FGFR1–3 kinase inhibitor derazantinib, in advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions or rearrangements ( FGFR2 F ), mutations ( FGFR2 M ), or amplifications ( FGFR2 A ), previously treated with chemotherapy. Approach & Results: Open-label, non-controlled Phase 2 trial. Patients with advanced iCCA, ≥1 prior chemotherapy, and FGFR2 F (Substudy 1) or FGFR2 M /FGFR A (Substudy 2), received once-daily oral derazantinib 300 mg until disease progression, unacceptable toxicity, consent withdrawal or investigator decision to stop. Efficacy was assessed by central radiology review using RECIST v1.1. Primary endpoints were objective response rate (ORR; Substudy 1) and 3-month progression-free survival (PFS3; Substudy 2). Other endpoints were PFS, ORR (Substudy 2), disease control rate (DCR), duration of response (DOR), and overall survival (OS). In Substudy 1, ORR and DCR were 22.3% (23/103 partial responses) and 75.7%, respectively; median (95% CI) PFS was 8.1 (5.5,8.3) months, DOR was 6.5 (4.6,9.2) months, and OS was 17.2 (12.5,22.4) months. In Substudy 2, PFS3 was 63% (27/43), ORR was 9.3% (3 partial, 1 complete response), DCR was 69.8%, and OS was 11.9 (8.4,15.9) months. There were no Grade 4 or 5 drug-related events. FGFR inhibitor class-specific toxicities included drug-related hyperphosphataemia (38%, Grade 3: 3%) and dry eye (36%). Nail disorders (10%, any grade or causality), stomatitis (5%), retinal events (5%), and palmar-plantar erythrodysesthesia (1%) were infrequent. Conclusions: In previously chemotherapy treated, FGFR-inhibitor-naïve patients with iCCA harboring FGFR2 fusions, mutations, or amplifications, derazantinib showed clinically meaningful efficacy with durable objective responses, and a manageable safety profile.
Novel Tool to Predict Primary Tumor Location in the Setting of Metastatic Cancer With Unknown Primary
Eldeeb, Kerolous , Badat, Saad , Perlow, Haley K , Baydoun, Atallah , Yang, Yifan , Wang, Ming , Zaorsky, Nicholas G

Mayo Clinic

JCO Oncology Practice | October 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/op-26-00212 | PMID 42863101 Get It

Purpose This study aimed to develop and validate a tool to predict the primary tumor site in patients with metastatic cancer of unknown primary using demographic and clinical variables, including imaging-derived sites of metastasis, without pathology or laboratory data. Methods In this population-based study, data were extracted from the SEER database. Patients diagnosed between 2010 and 2020 with a known primary cancer site, metastatic staging, and metastasis in the bone, liver, brain, and lungs were included. Patients were randomly split into training (70%) and/or testing (30%) sets. A total of 27 primary tumor sites were included. A gradient boosting model was trained to predict the primary tumor site, with random forest and classification tree models evaluated as comparators. Random guess and frequency-weighted guessing models were used for baseline comparison. Results A total of 689,715 patients were included from 9,208,295 queried. The most common primary cancer sites were non–small cell lung cancer (NSCLC) (n = 211,338), intestines (n = 64,187), and pancreas (n = 60,310). The baseline models achieved Top-5 accuracies of 0.179 for a random guess and 0.476 for a frequency-weighted guess. The gradient boosting model achieved Top-1, Top-3, and Top-5 accuracies of 0.40 ± 0.001, 0.680 ± 0.001, and 0.790 ± 0.001, respectively, across 100 Monte-Carlo replicates. Top-5 accuracy was highest for primary NSCLC (0.990 ± 0.001) and intestinal cancer (0.900 ± 0.003). Our model was most influenced by sex (gain = 0.27) and metastasis to bone (gain = 0.20). A web app was constructed: primarycancerpredictor.netlify.app. Conclusion This study developed and evaluated a gradient boosting machine learning model and a user-friendly web tool to aid in the diagnosis of cancer of unknown primary.
The efficacy of standard‐dose versus reduced‐dose everolimus in patients with advanced neuroendocrine tumors: A multicenter retrospective cohort study
Sahwan, Oudai , Mohamed, A , Jamal, Fares , Alsulaiman, Abdullah A , Bauernfeind, Jennah J , McGarrah, Patrick , Starr, Jason , Halfdanarson, Thorvardur R , Sonbol, Mohamad B

Mayo Clinic

Journal of Neuroendocrinology | October 5, 2026 | Volume: 38 | Issue: 10 | Pages: No page available

10.1111/jne.70278 | PMID 42833281 Get It

Abstract Everolimus 10 mg daily is the standard dose for advanced neuroendocrine tumors (NETs), but adverse events frequently necessitate dose reduction. As a result, oncologists often adopt a dose‐escalation strategy starting at 5 mg and increasing the dose as tolerated. In this multicenter study, we evaluated the effect of reduced dose (RD) and standard dose (SD) everolimus on survival, progression, and toxicity in patients with advanced NETs. We conducted a multicenter retrospective cohort study of patients with advanced NETs treated with everolimus at Mayo Clinic and University Hospitals (Cleveland, OH). Patients were grouped by starting dose (5 mg vs. 10 mg). Primary endpoints were overall survival (OS), real‐world progression‐free survival (rwPFS), and adverse events. Multivariable Cox models, inverse probability of treatment weighting (IPTW), and time‐varying dose sensitivity analysis were used to account for confounding and dose crossover. Among 170 patients (48 started on 5 mg; 122 on 10 mg), the 5 mg cohort was older, had worse ECOG PS, and was more heavily pretreated. Median OS was 43.7 months (5 mg) versus 81.5 months (10 mg; log‐rank p = .02). However, after multivariable adjustment ( N = 124 G1–G2 patients; 51 events), the association was no longer statistically significant (adjusted HR, 0.59; 95% CI, 0.31–1.12; p = .11). Median rwPFS was 7.0 versus 12.4 months (log‐rank p = .05); the adjusted rwPFS difference was not statistically significant (HR, 0.95; 95% CI, 0.56–1.61; p = .84). Nearly half (46.7%) of 10 mg starters required dose reduction. Any‐grade toxicity was more common with 10 mg (89% vs. 75%; p = .05). The apparent survival advantage of standard‐dose everolimus was substantially attenuated after adjustment. These findings do not establish dose equivalence and should be interpreted in the context of limited statistical power. Given its more favorable observed tolerability profile, RD everolimus warrants prospective evaluation as a starting strategy for patients at increased risk of treatment‐related toxicity who may not tolerate SD.
Projected Cancer Burden among Sexual and Gender Minorities by Generation in the United States
Xu, Crystal W. , Mani, Kyle , Dickstein, Daniel R. , Patel, Rohan K. , Wang, Ming , Xu, Yifei , Zaorsky, Nicholas G. , Wang, Ming , Dickstein, Daniel R

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: OF1-OF9

10.1158/1055-9965.epi-26-0504 | PMID 42770946 Get It

Abstract Background: Sexual and gender minority (SGM) representation is growing in the United States. This study estimated the future SGM cancer burden amidst shifting cancer patterns. Methods: Age-specific incidence data for breast, prostate, colorectal, lung, and melanoma were obtained from the Surveillance, Epidemiology, and End Results Program’s 12-registry database. Nordpred age-period-cohort models projected incidence through 2040 to 2044. Rates were applied to US Census population estimates and generation- and sex-specific SGM identification proportions from Gallup’s 2023 to 2024 surveys. Prophet was used for sensitivity analysis. Results: At ages 55 to 59, breast cancer cases among Millennial SGMs were 3,672% higher than among Silent Generation SGMs (34,850 vs. 924 cases), melanoma cases were 1,061% higher (5,526 vs. 476 cases), and colorectal cancer cases were 2,206% higher (23,594 vs. 1,023 cases). Compared with Generation X, Millennial prostate cancer cases were 142% higher (8,100 vs. 3,344 cases), and lung cancer cases were 169% higher (5,451 vs. 2,029 cases). By 2040 to 2044, Millennials were projected to account for 68.4% of breast cancer cases and 59.7% of colorectal cancer cases among SGMs. Conclusions: At ages 55 to 59, the 5-year cancer burden was projected to be 15 times higher among Millennials than Silent Generation SGMs (77,521 vs. 5,134 cases), driven primarily by the larger SGM population in younger generations. Oncology systems will need to prepare for the increase in cancer care demand. Impact: These findings identify a substantial generational shift in the SGM cancer burden and may inform oncology workforce capacity, culturally responsive cancer care, and healthcare system preparation for this growing population.
Phase 2 Study of Futibatinib in Combination with Pembrolizumab in Patients with FGF19 expressing Advanced Hepatocellular Carcinoma
Tran, Nguyen H, Palmer, Mathias Earl, Ulrich, Angela, McCue, Shaylene , Majeed, Umair, Halfdanarson, Thorvardur R, Carr, Ryan, Fonkoua, Lionel Aurelien Kankeu, Washburn, Leslie, Conboy, Caitlin, Torbenson, Michael, Starlinger, Patrick, Hallemeier, Christopher, Revzin, Alexander, Goenka, Ajit H. , Tran, Nguyen , Palmer, Mathias E , Mahipal, Amit , Ma, Wen Wee , Babiker, Hani , Halfdanarson, Thorvardur R , McWilliams, Robert R , Jin, Zhaohui , Carr, Ryan M , Fonkoua, Lionel Aurelien A Kankeu , Washburn, Leslie A , Conboy, Caitlin B , Graham, Rondell P , Starlinger, Patrick , Jethwa, Krishan , Goenka, Ajit Harishkumar , Venkatesh, Sudhakar K , Sonbol, Mohamad B , Bekaii-Saab, Tanios S , Roberts, Lewis R , Heimbach, Julie K , Ou, Fang-Shu , Tran, Nguyen H. , Mahipal, Amit , Wee, Wen , Babiker, Hani M. , Majeed, Umair , Hálfdánarson, Þorvarður R. , McWilliams, Robert R. , Jin, Zhaohui , Fonkoua, Lionel Aurelien Kankeu , Conboy, Caitlin B. , Graham, Rondell P. , Torbenson, Michael , Starlinger, Patrick , Jethwa, Krishan R. , Hallemeier, Christopher Leigh , Revzin, Alexander , Thompson, Scott M. , Venkatesh, Sudhakar K. , Sonbol, Mohamad Bassam , Borad, Mitesh J. , Bekaii‐Saab, Tanios , Gores, Gregory J. , Roberts, Lewis R. , Heimbach, Julie K. , Ou, Fang‐Shu

Mayo Clinic

The Oncologist | August 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/oncolo/oyag343 | PMID 42640574 Get It

Abstract Background Optimal treatment following first-line immunotherapy for advanced hepatocellular carcinoma (HCC) remains uncertain. This study evaluated futibatinib, a pan-FGFR inhibitor, combined with pembrolizumab in previously treated patients with FGF19-expressing HCC. Methods Eligible patients were ≥18 years old with advanced HCC, prior systemic therapy, Child-Pugh A-B7 liver function, ECOG 0–2, and FGF19 overexpression. Patients received futibatinib 20 mg orally daily plus pembrolizumab 200 mg intravenously every 3 weeks. The primary endpoint was progression-free survival at 6 months (PFS6). Secondary endpoints included overall survival (OS), objective response rate (ORR), quality of life, and safety. Results Between August 2021 and March 2024, 14 patients enrolled and 13 were evaluable. Median age was 72 years (range, 60–87), 53.8% were male, 92.3% had Child-Pugh A liver function, and all had received prior immunotherapy. Median progression-free survival was 15 weeks (95% CI, 9.0–NE), with a PFS6 rate of 23.1% (95% CI, 8.6–62.3%). ORR was 0% (95% CI, 0–24.7%), while stable disease was observed in 53.9% of patients. Median OS was 55.7 weeks (95% CI, 47.3–NE). Grade ≥3 adverse events occurred in 69.2% of patients, and grade ≥4 adverse events in 15.4%. One grade 5 event (acute-on-chronic kidney injury) was deemed unrelated to treatment. Common adverse events included hyperphosphatemia, fatigue, diarrhea, elevated transaminases, dry eye, nail changes, rash, and oral mucositis. Conclusions Futibatinib plus pembrolizumab demonstrated an acceptable safety profile but did not meet efficacy thresholds supporting further study in FGF19-expressing HCC. Effective post-immunotherapy treatment strategies remain an unmet need.
Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas
Minniti, Giuseppe, Brown, Paul D. , Vogelbaum, Michael A. , Ballman, Karla V. , Mercurio, Ann, Siegelin, Markus D., Tuohy, Kyle , Mansouri, Alireza , Simonelli, Matteo, DeStephano, David, Shuryak, Igor , Roy, Soumyajit , Hervey-Jumper, Shawn L., Horowitz, David P. , Sisti, Michael B. , Bruce, Jeffrey N. , Canoll, Peter, Neugut, Alfred I. , Iwamoto, Fabio M., Cheng, Simon K. , Kachnic, Lisa A. , Kinslow, Connor J , Brown, Paul D , Vogelbaum, Michael A , Ballman, Karla , Mercurio, Ann , Tuohy, Kyle , Mansouri, Alireza , Touat, Mehdi , Dehais, Caroline , Dipasquale, Angelo , Grinband, Jack , Yu, James B , Walch, Henry , Parker, Mitchell I , Shuryak, Igor , Roy, Soumyajit , Gallitto, Matthew , Horowitz, David P , McKhann, Guy M , Bruce, Jeffrey N , Ostrom, Quinn T , Neugut, Alfred I , Pike, Luke R G , Cheng, Simon K , Kachnic, Lisa A , Mehta, Minesh P , Wang, Tony J C , Minniti, Giuseppe , Siegelin, Markus D. , Kocakavuk, Emre , Ducray, François , Simonelli, Matteo , Yu, James B. , Hervey‐Jumper, Shawn L. , McKhann, Guy M. , Canoll, Peter , Ostrom, Quinn T. , Iwamoto, Fabio M., Mehta, Minesh P. , Wang, Tony J. C.

Mayo Clinic

Journal of Clinical Oncology | August 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-25-01846 | PMID 42585601 Get It

PURPOSE Age ≥40 years is regarded as a high-risk feature and an indication for adjuvant chemoradiotherapy for patients with lower-grade glioma in clinical practice guidelines. It is unclear whether age remains a relevant prognostic factor for contemporary definitions of lower-grade gliomas in the molecular era. METHODS The Prospective Gliomas Research (PROGRES) database contains individual patient-level data from 11 prospective clinical trials or observational registries of histologically defined lower-grade 2-3 oligodendroglioma or astrocytoma. We determined the association of age (18-39 years v ≥40 years) with progression-free survival (PFS) stratified by isocitrate dehydrogenase 1 or 2 ( IDH1/2 ) status, using log-rank tests and Cox regression models. We validated our findings in a separate multi-institutional retrospective cohort (Retrospective Glioma Research [REGRES] database). RESULTS We identified 1,619 and 1,292 eligible patients in the PROGRES and REGRES cohorts, respectively. IDH -wildtype tumors were more common in patients 40 years and older (38% v 5%, odds ratio: 11.3 [95% CI, 6.5 to 19.7]). Age was associated with PFS in IDH -wildtype (5-year PFS for ≥40 v 18-39 years: 6% v 24%, hazard ratio [HR], 1.74 [95% CI, 1.21 to 2.50]) but not in IDH -mutant glioma (60% v 59%, HR, 0.89 [95% CI, 0.76 to 1.05], P interaction < .001). In IDH -wildtype tumors, older age predicted aggressive molecular features, including TERT promoter mutation (65% v 28%), EGFR amplification (41% v 15%), and chromosome +7/–10 alteration (57% v 25%). In a pooled analysis of four clinical trials, age was not predictive of a benefit from chemoradiotherapy versus radiotherapy alone for IDH -mutant glioma. CONCLUSION In the absence of additional clinical or molecular risk factors, age alone should not be considered an indication for administration or deferral of adjuvant treatment. Practice guidelines should be revised to reflect contemporary prognostic factors in the molecular era.
Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004
Wierda, William G. , Dorritie, Kathleen , Gauthier, Jordan , Nath, Rajneesh, Kipps, Thomas J. , Riedell, Peter A. , Eradat, Herbert A., Kharfan‐Dabaja, Mohamed A. , Shah, Nirav N. , Solomon, Scott R., Stephens, Deborah M., Ermann, Daniel A., Arnason, Jon , Deol, Abhinav , Feldman, Tatyana , Ghosh, Monalisa , Tuazon, Sherilyn A., Perna, Serena K., Ou, San-San, Ananthakrishnan, Revathi , Rane, Neha, Papp, Eniko, Ansari, Sahar , Thompson, Ethan G., Okal, Abood, Peiser, Leanne, Chen, Yizhe , Sengupta, Sanhita , Wang, Jixian , Wierda, William G. , Dorritie, Kathleen , Kenderian, Saad S. , Kharfan-Dabaja, Mohamed A , Shah, Nirav N , Deol, Abhinav , Ma, Shuo , Schuster, Stephen J , Gergis, Usama , Vose, Julie , Soumerai, Jacob D , Besien, Koen van , Chen, Yizhe , Sengupta, Sanhita , Ray, Pradipta Ranjan , Siddiqi, Tanya , Kipps, Thomas J , Riedell, Peter A , Nath, Rajneesh , Eradat, Herbert, Stephens, Deborah M. , Andreadis, Charalambos Babis , Ma, Shuo , Schuster, Stephen J. , Vose, Julie M. , Soumerai, Jacob D. , Tuazon, Sherilyn A. , Perna, Serena , Ou, San‐San , Papp, Eniko , Ansari, Sahar, Siddiqi, Tanya

Mayo Clinic

Blood Journal | July 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2026033565 | PMID 42520199 Get It

Patients in the liso-cel plus ibrutinib cohort of the phase 1/2, open-label TRANSCEND CLL 004 study had relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and received liso-cel (50×106 [dose level (DL)1] or 100×106 [DL2] chimeric antigen receptor-positive T cells) with concurrent ibrutinib from enrollment through 90 days after liso-cel infusion or longer per investigator discretion. Primary end point was complete response/remission (CR)/CR with incomplete marrow recovery (CRi) by investigator assessment. Among 56 patients who received ibrutinib plus liso-cel (DL1, n=5; DL2, n=51), median (range) age was 64.5 years (44‒77), 98% had high-risk cytogenetics, 55% had progression on Bruton tyrosine kinase inhibitor and venetoclax failure, and median (range) number of prior therapies was 5 (1‒13). Median (range) follow-up was 24.8 months (3.1‒51.8). At DL2, CR/CRi rate was 45% (95% confidence interval [CI], 31‒60) and overall response rate was 86% (95% CI, 74‒94). Median (95% CI) duration of response was not reached (NR; 28.7‒NR) for patients with CR/CRi and 41.4 months (23.3‒NR) for all responders. Median (95% CI) progression-free survival was 31.4 months (20.1‒NR). In DL1+DL2, most common grade ≥3 treatment-emergent adverse events (TEAE) were neutropenia (52%) and anemia (41%). Cytokine release syndrome was reported in 80% of patients (grade 3, 4%; no grade 4/5), and neurological events in 41% (grade 3/4, 11%; no grade 5). Ibrutinib-related TEAEs were reported in 68% of patients (grade 3/4, 43%; no grade 5). Liso-cel plus ibrutinib demonstrated notable efficacy in patients with relapsed/refractory CLL/SLL with predictable and manageable safety. Clinicaltrials.gov: NCT03331198; NCT03435796.
Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Advanced Hepatocellular Carcinoma: A Propensity-Score-Matched Analysis
Ailawadi, Sarina , Mehravar, Sepideh , Murphy, Jennifer E., Storandt, Michael H. , Mahipal, Amit , Mahipal, Amit

Mayo Clinic

Biomedicines | July 21, 2026 | Volume: 14 | Issue: 7 | Pages: 1638

10.3390/biomedicines14071638 | PMID 42512110 Get It

Background: Atezolizumab plus bevacizumab (A + B) and durvalumab plus tremelimumab (D + T) are approved first-line systemic therapy options for advanced hepatocellular carcinoma (HCC), with no head-to-head comparison. In this propensity-matched analysis, we compared the survival of patients with advanced HCC who received either A + B or D + T therapy. Methods: Patients with advanced HCC who received A + B or D + T treatment in the first-line setting were identified using the TriNetX platform, a health research network that provides access to electronic health record data from 112 healthcare organizations. Propensity-score-matched (PSM) analysis was conducted, and the median overall survival (OS) was estimated using the Kaplan–Meier method. Results: We identified 2819 patients with HCC who were treated with A + B or D + T: 2031 patients received A + B and 788 received D + T. Compared to patients in the A + B cohort, those who received D + T were more likely to be older (median age: 68.4 vs. 66.9 years), have lower platelet counts (186.8 vs. 201.3), higher prevalence of hypoalbuminemia with levels < 2.7 g/dL (35.2% vs. 28.4%), higher prevalence of bilirubin levels between 2.0 and 2.9 mg/dL (28.8% vs. 23.8%), and decreased INR with levels between 0.0 and 1.6 (92.1% vs. 86.3%). After PSM, 1536 patients were included in the survival analyses, with all variables adequately matched. There was no significant difference in the median OS between those receiving A + B or D + T [16.3 vs. 22.5 months, hazard ratio (HR) 0.89, 95% confidence interval (CI) 0.76–1.0]. Higher rates of immune-mediated colitis were noted in the D + T group. Conclusions: Similar survival rates were observed among patients with advanced HCC who received A + B and D + T in the first-line setting. Our study suggests that both A + B and D + T are valid treatment options, and that therapy can be tailored based on comorbidities, adverse effects, and patient preferences.
Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers
Shah, Priyanshi , Peersen, Anina, Sahai, Vaibhav , Mahipal, Amit , Naleid, Nikolas , Borad, Mitesh J. , Bekaii‐Saab, Tanios , Sonbol, Mohamad Bassam , Majeed, Umair , Babiker, Hani M. , O’Donnell, Conor, Malla, Midhun , Conboy, Caitlin B. , Fonkoua, Lionel Kankeu, Washburn, L. , Peterson, Nicole , Carr, Ryan M., Starlinger, P, Smoot, Rory, Warner, Susanne, Ilyas, Sumera L., Heimbach, Julie, Borad, Mitesh J , O'Donnell, Conor D J , Conboy, Caitlin B , Washburn, Leslie A , Halfdanarson, Thorvardur R , Peterson, Nicole , McWilliams, Robert R , Graham, Rondell P , Gores, Gregory J. , Roberts, Lewis R , Ou, Fang-Shu , Tran, Nguyen , Mahipal, Amit , Sonbol, Mohamad B , Bekaii-Saab, Tanios S , Babiker, Hani , Majeed, Umair , Sahai, Vaibhav , Peersen, Anina, Gupta, Garima , Fonkoua, Lionel Aurelien Kankeu , Hálfdánarson, Þorvarður R. , McWilliams, Robert R. , Carr, Ryan M , Graham, Rondell P. , Starlinger, Patrick, Warner, Susanne, Ilyas, Sumera I. , Gores, Gregory J. , Roberts, Lewis R. , Heimbach, Julie K. , Ou, Fang‐Shu , Tran, Nguyen H.

Mayo Clinic

JCO Precision Oncology | July 10, 2026 | Volume: 10 | Issue: 7 | Pages: No page available

10.1200/po-25-01156 | PMID 42430699 Get It

PURPOSE Deficient mismatch repair/microsatellite instability (dMMR, MSI-H) in biliary tract cancers (BTCs) is observed in 1%-5% of tumors. MSI-H across solid tumors has demonstrated durable response to immune checkpoint inhibitors (ICIs) regardless of the anatomic location. Here, we describe clinical outcomes and surgical conversion of MSI-H BTC treated with ICIs. Patients and Methods We conducted a multicenter, retrospective analysis of BTC patients with dMMR/MSI-H between 2017 and 2024 at Mayo Clinic, University of Michigan, and University Hospitals Seidman Cancer Center. Outcomes of interest were surgical resection rate, rate of pathologic response, 2-year overall survival (OS; time from initiation of treatment to death/last follow-up), and time to treatment discontinuation (TTD; time from initiation of treatment to cessation because of any cause). Analyses were descriptive. RESULTS Thirty patients with MSI-H BTC were identified: 19 with cholangiocarcinoma, three with gallbladder cancer, and 8 with BTC undefined. The median age at diagnosis was 61.5 years (range, 26-86). Twenty-six (86.7%) patients had advanced stage at diagnosis. Twenty-seven patients (90%) received first-line systemic therapy, and 13 (48.1%) continued onto second line. Six patients (23.1%) were restaged to resectable from advanced disease after ICI therapy and underwent resection; all remained recurrence-free at last follow-up. Of these six patients, 3 (50%) achieved a pathologic complete response. Among those receiving first-line therapy, the median TTD was 9.9 months (95% CI, 5.7 to 14.5 months) and the 2-year OS was 73% (95% CI, 56% to 94%). CONCLUSION ICI therapy in patients with MSI-H BTC demonstrated durable response and downstaged some BTC to a resectable stage. dMMR/MSI-H should be performed up-front to guide treatment decisions.
Bone-Modifying Agents in Metastatic Castration-Resistant Prostate Cancer
Gebrael, Georges, Ostrowski, Micah , Li, Haoran, Roy, Soumyajit, Maughan, Benjamin L, Guha, A, Antonarakis, Emmanuel S., McKay, Rana R., Agarwal, Neeraj, Swami, Umang , Guha, Avirup , Riaz, Irbaz Bin , Guha, Avirup , Özay, Zeynep İrem , Jo, Yeonjung , Gebrael, Georges , Thomas, Vinay Mathew , Li, H. Harold , Graf, Ryon P. , Roy, Soumyajit, Maughan, Benjamin L. , Antonarakis, Emmanuel S. , McKay, Rana R. , Agarwal, Neeraj

Mayo Clinic

JAMA Network Open | June 24, 2026 | Volume: 9 | Issue: 6 | Pages: e2620084

10.1001/jamanetworkopen.2026.20084 | PMID 42340725 Get It

This cohort study examines patterns of bone-modifying agent use from 2013 to 2024 among men with metastatic castration-resistant prostate cancer.